The following is a description of a study from one of the many researchers that our organization has funded.

Autoimmune Disorder Target: DRAK2

Martina Gatzka, Ph.D.
University of California
Irvine, California
Modulation of central and peripheral immunological tolerance by DRAK2, a negative regulatory of lymphocyte signaling

This is Dr. Gatzka’s second year of work in autoimmune disorders, studying the body’s natural surveillance mechanisms. When T lymphocytes (T cells), a type of white blood cell, cannot distinguish between self and non-self tissues, they contribute to inflammation and tissue destruction in autoimmune diseases such as RA, lupus, and MS. Dr. Gatzka is studying a particular surveillance mechanism that keeps T cells from going awry called DRAK2 (DAP-related apoptotic kinase-2). Her research applies cutting-edge immunological and molecular biological methods to investigate how a DRAK2 modulates T cell activation and tolerance in a mouse model of rheumatoid arthritis, collagen-induced arthritis (CIA).

Identifying strategies to specifically block and eliminate self-reactive T lymphocytes is key to the development of efficient new therapies for these immune mediated diseases.

You may return to the list of research that we have funded.
Translate »

Connect with ANRF Today!

Stay up -to-date with the latest arthritis news, stories and info.​

Make a Donation

Make a one-time or recurring donation and know that you are making a difference by funding cutting-edge arthritis research.

Skip to content